SOURCE-LINKED STUDY SUMMARY
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
Abstract summarizedQuality not appraised
- What was studied
- This single-centre, masked, randomized phase 1b/2a trial assessed injected amycretin versus placebo. Adverse events were primary; weight change was secondary.
- Who / model studied
- 125 adults with overweight or obesity were randomized: 101 to amycretin and 24 to placebo. Eligibility required ages 18–55.
- Studied dose & schedule
- Weekly subcutaneous treatment escalated from 0.3 mg to 60 mg over 36 weeks, or to maintenance doses of 20 mg (36 weeks), 5 mg (28 weeks), or 1.25 mg (20 weeks).
- What the study found
- At 36 weeks, estimated weight loss was 24.3% with 60 mg versus 1.1% with placebo. Gastrointestinal events were most common, generally mild to moderate, and resolved by study end.
- Limitations & context
- Many participants withdrew, often for reasons unrelated to treatment-emergent adverse events, limiting interpretation of the results.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(25)01185-7